RichardAplencMD

Pediatric Hematology & Oncology • Philadelphia, PA

Professor of Pediatrics, Perelman School of Medicine

Join to view full profile

Dr. Aplenc is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Aplenc's full profile

Already have an account?

Office
3401 Civic Center Blvd
Children's Hospital Of Philadelphia - Hem/Onc
Philadelphia, PA 19104
Phone+1 215-590-3535

Fax+1 215-590-3992

Education & Training

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 1997 - 2000
University of California (San Diego) Medical CenterResidency, Pediatrics, 1994 - 1997
University of Virginia School of MedicineClass of 1994

Certifications & Licensure

PA State Medical License 1997 - 2024
CA State Medical License 1996 - 2000
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes Start of enrollment: 2002 Jul 01
Completed
Phase 1
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate Start of enrollment: 2006 Mar 01
Completed
Phase 1
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2006 Aug 01
Completed
Phase 3
DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia Start of enrollment: 2004 May 13
Completed
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia Start of enrollment: 2009 Jun 01
Terminated
Phase 1
Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia Start of enrollment: 2009 Dec 01
Completed
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Start of enrollment: 2011 Dec 01
Terminated
Phase 1, Phase 2
Home Away From Home - Medical Outcomes Start of enrollment: 2015 Jun 01
Completed
Home Away From Home - Quality of Life Surveys Start of enrollment: 2016 Sep 01
Completed
Home or Away From Home - Descriptive Interviews (Aim 2) Start of enrollment: 2015 Aug 01
Completed
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia Start of enrollment: 2020 Jan 08
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

3737 citations
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L. Maude, Noelle Frey, Pamela A. Shaw, Richard Aplenc, David M. Barrett
The New England Journal of Medicine. 2014-10-15
714 citations
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey, Simon F. Lacey, Pamela A. Shaw, J. Joseph Melenhorst, Shannon L. Maude
Cancer Discovery. 2016-06-01
2503 citations
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
Stephan A. Grupp, Michael Kalos, David M. Barrett, Richard Aplenc, David L. Porter
The New England Journal of Medicine. 2013-04-17

Abstracts/Posters

Disparities in Barriers and Facilitators of Acute Leukemia Diagnosis in Young Patients
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report ...
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Response to Sorafenib in FLT3/ITD AML Is Depedent on Co-Occurring Mutational Profile
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Occurrence and Resolution of Anthracycline Cardiotoxicity and Impact on Treatment Outcomes Among Children Treated on the AAML1031 Clinical Trial: A Report from the Chi...
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a ChildrenÍs Onc...
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Rates of Laboratory Adverse Events By Chemotherapy Course for Pediatric Acute Leukemia Patients within the Leukemia Electronic Abstraction of Records Network (LEARN)
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS)
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Delays in Therapy Do Not Impact Survival in Childhood Acute Lymphoblastic Leukemia: A Report from the Learn Consortium
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Home or Away from Home: A Multi-Institution Study Comparing Medical Outcomes, Patient Perspectives, and Health-Related Quality of Life for Outpatient Versus Inpatient ...
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Early Broad-Spectrum Antibiotics and Risk of Acute Graft-Versus-Host Disease in Children: An Analysis from the Center for International Blood and Marrow Transplantatio...
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long Non-Coding RNAs (lncRNAs) Are Highly Associated with Disease Characteristics and Outcome in Pediatric Acute Myeloid Leukemia _ a COG and Tpaml Study
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene _ a COG/Tpaml Study
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the ChildrenÍs Oncology Group
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Pa...
Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Effect of intensification of induction II chemotherapy and liberalization of stem cell donor source on outcome for children with high risk acute myeloid leukemia: A re...
2019 ASCO Annual Meeting - 6/1/2019
Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Pediatric Patient-Reported Symptom Tracking in Oncology (Pedi-PReSTO): A Feasibility Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Comparing the Liver Function of Children with Acute Lymphoblastic Leukemia (ALL) Receiving Standard or High Intensity Treatment during the Interim Maintenance I Phase ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Emily Whitehead, First Pediatric Patient to Receive CAR T-cell Therapy, Celebrates Cure 10 Years LaterMay 11th, 2022
Remembering Alvin Zipursky, Paul Frenette, and MoreSeptember 1st, 2021
Children's Hospital of Philadelphia Names Chief of Hematologic MalignanciesJuly 13th, 2021
Join now to see all

Grant Support

Genetic Predictors Of AML Treatment ResponseNational Cancer Institute2010–2012
Genetic Predictors Of Leukemia Therapy ResponseNational Cancer Institute2005–2009